Stereotactic radiosurgery for large brain metastases

Research output: Chapter in Book/Report/Conference proceedingChapter

7 Scopus citations


Surgical resection still remains the mainstay of treatments for large brain metastases if feasible. Recently, stereotactic radiosurgery (SRS) using low-dose, 11-to 12-Gy marginal prescription dose, was tried to document the benefit for patients with large brain metastases when it was used as a primary or salvage treatment. Many large brain metastases responded promptly and showed favorable outcome after SRS. More than half of the patients recovered from their neurological deficits within 1 month after SRS. However, not negligible portion of patients were suffered from the adverse radiation effects and the final outcome was not same as that of optimal sized tumors for SRS. The safety of the current dose scheme for large brain metastases should be reevaluated in the near future, considering the relatively high rate of radiation-related injuries observed. Even with modern technology, SRS alone may not have any benefit in tumor volume reduction and survival for brain metastases larger than 26 cm 3 (an approximate maximum diameter of 3.5 cm).

Original languageEnglish
Title of host publicationCurrent and Future Management of Brain Metastasis
EditorsDong Gyu Kim, Dade Lunsford
Number of pages13
StatePublished - 5 Dec 2012

Publication series

NameProgress in Neurological Surgery
ISSN (Print)0079-6492
ISSN (Electronic)1662-3924

Cite this

Han, J. H., Kim, D. G., Kim, C. Y., Chung, H. T., & Jung, H. W. (2012). Stereotactic radiosurgery for large brain metastases. In D. G. Kim, & D. Lunsford (Eds.), Current and Future Management of Brain Metastasis (pp. 248-260). (Progress in Neurological Surgery; Vol. 25).